Home | RheumNow

Recent News

Mixed Drinks, Mixed Results (10.30.2026)
Save

Jack Cush, MD

Oct 30, 2026

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.

Read Article

FDA has approved the IL-23 inhibitor tildrakizumab (Ilumya) use in adults with active psoriatic arthritis (PsA), expanding the interleukin indications beyond moderate-to-severe plaque psoriasis. (Based on INSPIRE-1/2; >800 adults, 52-week RCTs) https://t.co/tCKZQwf74A https://t.co/Qffr1ZAMd7

FDA Approves Tildrakizumab for Psoriatic Arthritis in Adults

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? The treatment of active TAK is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage. https://t.co/J1EQHGzR5O https://t.co/i59kRGJCoK

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? | RheumNow

Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/JCTszYa57m

Novartis receives European Commission approval for Cosentyx® in polymyalgia rhe…

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/xTlr5lrwUz

"We really need to ask every patient who has psoriasis about their joints” – Dr. Ahmad Amin, Dermatologist Watch Dr. Amin and Dr. Saakshi Khattri discuss the link between skin and joints in PsA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/rp2e5oknVF https://t.co/nf2vpvNJuV

PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives | RheumNow

Prof. Mease shares this important slide illustrating how excessive adipose tissue contributes to PsA dev’t 👇 Dysfunctional adipose tissue enables overall amplification of inflammation in obese pts with PsA @RheumNow #APLAR2026 https://t.co/1YtcqxM4B3

https://x.com/RHEUMarampa/status/2116085070146801824/photo/1

Optimizing GC use in SLE: In arthritis, avoid oral GC - consider NSAIDS, csDMARDs, small molecules or biologics On GC initiation, hit hard w/pulse MP then taper early and rapidly In LN, treat aggressively bec damage is driven by dse activity, not meds @RheumNow #APLAR2026 https://t.co/Q5gFpr8P9k

OA injections span three tiers: symptom-modifying (steroid, HA, polynucleotides), structure-oriented (sprifermin, Wnt inhibitors) and biologic (PRP, MSCs, EVs). None looks far superior to steroid or HA for symptoms; structural benefit is the goal. OA SIG #APLAR26 @RheumNow https://t.co/4R6Oxd0BvL

The @RheumNow crew together at #APLAR2026 https://t.co/9YizHIFprF

https://x.com/JihaRheum/status/2116043911718441344/photo/1

T cell clone in AxSpA Trvb9 & Trav 21 B27 pos pts - t cell engager developed @RheumNow #APLAR2026 https://t.co/Jt7XBu3Kok

https://x.com/drpnash/status/2116405424090153127/photo/1

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic https://t.co/TPqPKP5MRl

Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings Listen to leading rheumatology and dermatology experts for an engaging discussion on the evolving landscape of Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE). https://t.co/lJOzeR81AS

ACR Convergence 2026 is almost here. Whether you’re attending in person or following from afar, RheumNow will bring you the research, clinical updates and expert insights you need to know. Join us for #ACR26 coverage beginning November 7th at https://t.co/ofGKCCNQnE. #ACR26 https://t.co/lMJSrkxMlN

Home | RheumNow

The Efficacy of Ianalumab in Sjögren’s Disease The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or https://t.co/YStzIFq5Bx

Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ PDE4i & poorer baseline activity & PROs https://t.co/BhxAMtjsZV

Patients with type 2 SLE present with fatigue, pain, brain fog and mood changes. Type 1 & 2 often coexist but type 2 SLE impacts QOL. @RheumNow #lupus #APLAR2026 https://t.co/aMtoIprPWG

https://x.com/RHEUMarampa/status/2115970283438051839/photo/1

Excites to report on #APLAR26 in Seoul, S. Korea for @RheumNow along with Drs. @RHEUMarampa and Peter Nash https://t.co/QImSxM7Izi

https://x.com/JihaRheum/status/2115969557945032869/photo/1

24-Week Interim Findings from a Randomized Phase 2 Study of Iptacopan (LNP023) Indicate High Remission Rates in Participants with Active ANCA-Associated Vasculitis https://t.co/cUNMo2ngeE and liver safety over time is?

24-Week Interim Findings from a Randomized Phase 2 Study of Iptacopan (LNP023) …

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis https://t.co/RPD7FkgEdQ anti-TRVB and anti-TRAV for your B27 AxSpA patients ( and needs looking at B27 positive PsA ) watch this space

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Ass…

Video

Podcasts

Mixed Drinks, Mixed Results (10.30.2026)
Oct 30, 2026
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
Oct 28, 2026
Double Trouble (10.23.2026)
Oct 23, 2026
Troubles with ‘Gut Feelings’
Oct 16, 2026

Submit your Rheumatology question or case here

Therapeutic Updates

PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives

Sponsored by AbbVie Medical Affairs + Health Impact

Oct 01, 2026

Dr. Saakshi Khattri hosts dermatologist Dr. Ahmad Amin and gastroenterologist Dr. Joshua Steinberg to discuss multidisciplinary care in PsA and other immune-mediated inflammatory diseases. Learn how signals in the skin and gut may prompt the need for collaboration across specialties to support better patient outcomes that extend beyond the joints.

Read Post